228 related articles for article (PubMed ID: 26518951)
1. Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand.
Chiasakul T; Townamchai N; Jutivorakool K; Chancharoenthana W; Thongprayoon C; Watanatorn S; Avihingsanon Y; Praditpornsilpa K; Srisawat N
Transplant Proc; 2015 Oct; 47(8):2460-4. PubMed ID: 26518951
[TBL] [Abstract][Full Text] [Related]
2. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
Kaminski H; Jarque M; Halfon M; Taton B; Di Ascia L; Pfirmann P; Visentin J; Garrigue I; Déchanet-Merville J; Moreau JF; Crespo E; Montero N; Melilli E; Meneghini M; Pascual M; Couzi L; Manuel O; Bestard O; Merville P
J Infect Dis; 2019 Jul; 220(5):761-771. PubMed ID: 31157865
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
4. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
[TBL] [Abstract][Full Text] [Related]
5. Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis - a cohort single-center study.
de Paula MI; Bowring MG; Shaffer AA; Garonzik-Wang J; Bessa AB; Felipe CR; Cristelli MP; Massie AB; Medina-Pestana J; Segev DL; Tedesco-Silva H
Transpl Int; 2021 Feb; 34(2):339-352. PubMed ID: 33314321
[TBL] [Abstract][Full Text] [Related]
6. Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study.
Chitasombat MN; Watcharananan SP
F1000Res; 2018; 7():1568. PubMed ID: 30473779
[No Abstract] [Full Text] [Related]
7. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
Shah AP; Chen JM; Fridell JA
Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
[TBL] [Abstract][Full Text] [Related]
8. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
Bruminhent J; Dajsakdipon T; Ingsathit A; Supaporn T; Prommool S; Watcharananan SP
Transplant Proc; 2020 Apr; 52(3):829-835. PubMed ID: 32113693
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome.
Watcharananan SP; Louhapanswat S; Chantratita W; Jirasiritham S; Sumethkul V
Transplant Proc; 2012 Apr; 44(3):701-5. PubMed ID: 22483472
[TBL] [Abstract][Full Text] [Related]
11. Low Immunologic Risk Living Related Renal Transplant Using Very Low-Dose Antithymocyte Globulin as Induction Therapy: A Single Tertiary Hospital Experience.
Jalalonmuhali M; Ng KP; Ong CS; Lee YW; Wan Md Adnan WAH; Lim SK
Transplant Proc; 2020; 52(6):1709-1714. PubMed ID: 32448669
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
13. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
[TBL] [Abstract][Full Text] [Related]
14. The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.
Low CY; Hosseini-Moghaddam SM; Rotstein C; Renner EL; Husain S
Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28613442
[TBL] [Abstract][Full Text] [Related]
15. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
16. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
17. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
Kim T; Lee YM; Lee SO; Choi SH; Kim YS; Woo JH; Sung H; Jung JH; Shin S; Kim YH; Kang YA; Lee YS; Lee JH; Lee JH; Lee KH; Park SK; Han DJ; Kim SH
Korean J Intern Med; 2016 Sep; 31(5):961-70. PubMed ID: 27055664
[TBL] [Abstract][Full Text] [Related]
18. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
Jewani PK; Pouch SM; Kissling KT
Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients.
Lee YM; Kim YH; Han DJ; Park SK; Park JS; Sung H; Hong HL; Kim T; Kim SH; Choi SH; Kim YS; Woo JH; Lee SO
Transpl Infect Dis; 2014 Jun; 16(3):397-402. PubMed ID: 24810355
[TBL] [Abstract][Full Text] [Related]
20. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Brady RL; Green K; Frei C; Maxwell P
Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]